Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.
Br J CancerJul 2, 2026 (epub)
Chia-Jui Yen, Ming-Huang Chen, Yen-Yang Chen et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase IIa trial evaluated the efficacy and safety of CVM-1118 in 43 patients with advanced well-differentiated neuroendocrine tumors (NETs) who were refractory to standard therapies. The study found a median progression-free survival (PFS) of 10.5 months and a disease control rate (DCR) of 77%, indicating promising outcomes for this novel treatment.
Key findings
- Median progression-free survival (PFS) was 10.5 months (95% CI, 5.6-22.3).
- Objective response rate (ORR) was 3%, while disease control rate (DCR) was 77%.
- Median overall survival (OS) was not reached (95% CI, 23.8-NR).
- Treatment-related adverse events occurred in 44%, primarily grades 1-2.
Why it matters
The findings suggest that CVM-1118 may offer a new therapeutic option for patients with advanced NETs who have limited treatment alternatives, potentially improving disease management and patient outcomes.